BRIEF-Novartis To Acquire The Medicines Company For $9.7 bln

REG-NOVARTIS TO ACQUIRE THE MEDICINES COMPANY FOR USD 9.7 BN, ADDING INCLISIRAN, A POTENTIALLY TRANSFORMATIONAL INVESTIGATIONAL CHOLESTEROL-LOWERING THERAPY TO ADDRESS LEADING GLOBAL CAUSE OF DEATH

 NOVARTIS – DEAL EXPECTED TO MODESTLY DILUTE CORE EPS VERSUS A NO DEAL SCENARIO DURING NEXT FEW YEARS AS CO INVESTS FOR A SUCCESSFUL LAUNCH OF INCLISIRAN

 TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES

 NOVARTIS PLANS TO FINANCE TRANSACTION THROUGH AVAILABLE CASH AND SHORT- AND LONG-TERM BORROWINGS

 TRANSACTION IS EXPECTED TO CLOSE IN Q1 OF 2020, SUBJECT TO SATISFACTION OR WAIVER OF ALL CLOSING CONDITIONS

ASSUMING COMPLETION IN Q1 OF 2020.

reuters.com

 

logo

Logistic 3PL
Center Biokon

We are in social networks

9.00 to 18.00
+38 (044) 585-11-80
+38 (044) 585-11-81
trade@biocon-bc.com
9 Boryspilska St., Velyka Olexandrovka Village, Boryspilskyi District, 08320, Kyiv Region

© 2021 «BIOKON» All rights reserved.